Back to Journals » Research and Reports in Urology » Volume 2

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma

Authors Morel A, Talbot D

Published 29 June 2010 Volume 2010:2 Pages 99—108

DOI https://doi.org/10.2147/RRU.S7234

Review by Single-blind

Peer reviewer comments 3


Armand Morel, Denis Talbot

1Department of Medical Oncology, University of Oxford, Oxford, Oxfordshire, UK

Abstract: Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refractory disease, there is currently no standard treatment. Vinflunine, a second-generation Vinca alkaloid, is the first chemotherapeutic agent to be evaluated in a large UC second-line population. This review discusses the pre-clinical and clinical data published, and compares vinflunine to alternative single agents and combination regimens tested in this setting. Based on the results of the phase II and III clinical trials, there appears to be sufficient evidence to support the use of vinflunine in the second-line setting.

Keywords: vinflunine, Vinca alkaloid, urothelial carcinoma, transitional cell carcinoma, bladder cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]